Department of Pediatrics, Yonsei University College of Medicine, Severance Fecal Microbiota Transplantation Center, Severance Hospital, Severance Fecal Microbiota Transplantation Center, Severance Hospital, Seoul, Republic of Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
J Gastroenterol Hepatol. 2022 Sep;37(9):1822-1832. doi: 10.1111/jgh.15903. Epub 2022 Jun 10.
Discordant reports of the signature gut microbes involved in nonalcoholic fatty liver disease (NAFLD) have hampered understanding of the pathogenesis of the disease, and thus its diagnosis. Thus, we investigated diagnostic factors and the potential mechanisms for heterogenous NAFLD based on the gut environment, including microbes and functional pathways.
Stools from 16 biopsy-proven NAFLD patients were analyzed for bacterial taxonomy and functional pathways based on 16s rRNA gene sequencing. Data from the physical examination, serum biochemistry, and the gut environment were subjected to a decision tree classifier to identify diagnostic markers.
We identified two NAFLD subpopulations: those with and without a gut microbiota similar to health controls (HCs), defined as P and P patients, respectively. Stools of P patients were significantly populated with Enterobacteriaceae and were inferred to be rich in metabolites degraded from dicarboxylic acid sugars. Significant colonization of Prevotella was observed in the stools of P patients, in parallel with enrichment of metabolites from heme b biosynthesis and sulfate reduction. As a potential mechanism, we suggest that protoporphyrin IX and/or protoheme from Prevotella participates in hepatic injury, and that endogenous hydrogen sulfide increases serum IL-6 level in P patients. However, endotoxin-producing Enterobacteriaceae are thought to produce glycerate, triggering a peroxisome proliferator- activated receptor-alpha-mediated decrease in IL-6 level and fat accumulation in P patients.
Heterogenous NAFLD subpopulations were identified, defined according to gut microbial composition and their potential underlying pathogenic mechanisms; our results raise the possibility of personalized treatment for NALFD patients.
非酒精性脂肪性肝病(NAFLD)相关特征性肠道微生物的报告结果相互矛盾,这阻碍了人们对该疾病发病机制的理解,进而影响了其诊断。因此,我们基于肠道环境(包括微生物和功能途径)研究了异质性 NAFLD 的诊断因素和潜在机制。
我们基于 16S rRNA 基因测序分析了 16 例经活检证实的 NAFLD 患者的粪便细菌分类和功能途径。我们将体检、血清生化和肠道环境数据输入决策树分类器,以确定诊断标志物。
我们发现了两种 NAFLD 亚群:肠道微生物与健康对照相似(HC)的患者(P 患者)和肠道微生物与 HC 不同的患者(P 患者)。P 患者的粪便中显著定植了肠杆菌科,且推断其富含二羧酸糖降解代谢物。P 患者粪便中普雷沃氏菌属显著定植,同时富含血红素 b 生物合成和硫酸盐还原代谢物。作为一种潜在机制,我们提出普雷沃氏菌属的原卟啉 IX 和/或原血红素可能参与肝损伤,而内源性硫化氢增加 P 患者的血清 IL-6 水平。然而,产内毒素的肠杆菌科可能会产生甘油酸,触发过氧化物酶体增殖物激活受体-α介导的 P 患者 IL-6 水平降低和脂肪堆积。
根据肠道微生物组成及其潜在的致病机制,我们确定了异质性 NAFLD 亚群;我们的研究结果提出了针对 NAFLD 患者进行个体化治疗的可能性。